ConductScience.org, home

Library / Genes

TOP2A: DNA topoisomerase II alpha

1 protein, 90 patents, 26 drugs, 4,309 trials, 7,493 NIH grants and 23,720 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolTOP2AHGNC
NameDNA topoisomerase II alphaHGNC
NCBI Gene ID7153NCBI Gene
HGNC IDHGNC:11989HGNC
EnsemblENSG00000131747NCBI Gene
AliasesTOP2, TOP2alpha, TOPIIA, TP2ANCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P11388DNA topoisomerase 2-alpha1,53115Ensembl, GeneID, HGNCUniProt

Patents 90

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
JP 2026000906 A2026-01-0643P11388Espacenet
EP 4650780 A22025-11-1913710P11388Espacenet
EP 4641201 A22025-10-2915789P11388Espacenet
EP 4641202 A22025-10-296794P11388Espacenet
JP 2025517969 A2025-06-1215789P11388Espacenet
JP 2025517970 A2025-06-1213710P11388Espacenet
KR 1020250017231 A2025-02-046794P11388Espacenet
JP 2024123008 A2024-09-108744P11388Espacenet
JP 2024522178 A2024-06-1112P11388Espacenet
US 11976334 B22024-05-07206P11388Espacenet

Drugs 26

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ALDOXORUBICINCHEMBL2107818DNA topoisomerase II alpha inhibitorINHIBITORChEMBL
AMRUBICINCHEMBL1186894DNA topoisomerase II alpha inhibitorINHIBITORChEMBL
AMRUBICIN HYDROCHLORIDECHEMBL481958DNA topoisomerase II alpha inhibitorINHIBITORChEMBL
AMSACRINECHEMBL43DNA topoisomerase II inhibitorINHIBITORChEMBL
BECATECARINCHEMBL2107313DNA topoisomerase II inhibitorINHIBITORChEMBL
BERUBICINCHEMBL2110580DNA topoisomerase II inhibitorINHIBITORChEMBL
BERUBICIN HYDROCHLORIDECHEMBL2103796DNA topoisomerase II inhibitorINHIBITORChEMBL
C-1311CHEMBL338604DNA topoisomerase II inhibitorINHIBITORChEMBL
DAUNORUBICINCHEMBL178DNA topoisomerase II alpha inhibitorINHIBITORChEMBL
DAUNORUBICIN CITRATECHEMBL1200475DNA topoisomerase II alpha inhibitorINHIBITORChEMBL

Trials 4309

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07604766DOXORUBICINPHASE3ClinicalTrials.gov
NCT07604233IDARUBICINPHASE1/PHASE2ClinicalTrials.gov
NCT07588698DOXORUBICINPHASE2ClinicalTrials.gov
NCT07585734DAUNORUBICINPHASE1/PHASE2ClinicalTrials.gov
NCT07583550ETOPOSIDEPHASE2ClinicalTrials.gov
NCT07583511ETOPOSIDEPHASE2ClinicalTrials.gov
NCT07583511TENIPOSIDEPHASE2ClinicalTrials.gov
NCT07565324DOXORUBICINPHASE2ClinicalTrials.gov
NCT07560826DOXORUBICINPHASE2ClinicalTrials.gov
NCT07552324DOXORUBICIN HYDROCHLORIDEPHASE2ClinicalTrials.gov

NIH grants 7493

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA016672Cancer Center Support Grant1102,025NIH's project files
P30CA008748Cancer Center Support Grant642,025NIH's project files
T32CA009582Biochemical and Chemical Training for Cancer Research602,025NIH's project files
P30CA021765Cancer Center Support Grant (CCSG)592,025NIH's project files
ZIABC006150DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs532,025NIH's project files
ZIABC006161DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs412,025NIH's project files
P30CA016058Cancer Center Support Grant372,025NIH's project files
P30CA076292Moffitt Cancer Center Support Grant282,025NIH's project files
P30CA006973Regional Oncology Research Center272,025NIH's project files
P30CA016056Roswell Park Cancer Center Support Grant232,025NIH's project files

Papers 23720

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42827180PubTator, text miningPubMed
42818333PubTator, text miningPubMed
42818186PubTator, text miningPubMed
42817708PubTator, text miningPubMed
42816485PubTator, text miningPubMed
42805543PubTator, text miningPubMed
42800166PubTator, text miningPubMed
42797318PubTator, text miningPubMed
42794427PubTator, text miningPubMed
42793985PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license